



PRODUCT: **ZOKINVY®**

COMPANY: Eiger BioPharmaceuticals, Inc.

THERAPEUTIC AREA & INDICATION:
Treatment of genetic diseases of premature
aging in children and young adults

ABOUT THE PRODUCT

Zokinvy is a disease-modifying agent that has demonstrated a statistically significant survival benefit in children and young adults with Progeria, a universally fatal premature aging disease. In patients with Progeria, Zokinvy reduced the incidence of mortality by 60% ($p=0.0064$) and increased average survival time by at least 2.5 years. Some patients with Progeria have received continuous Zokinvy therapy for >10 years.

The approval of Zokinvy is the culmination of an innovative and pioneering partnership between Eiger and The Progeria Research Foundation (PRF) to bring the first FDA-approved therapy to the Progeria community. Eiger also offers a global expanded access program.